TD Cowen Cuts Surgery Partners (NASDAQ:SGRY) Price Target to $20.00

Surgery Partners (NASDAQ:SGRY) had its price target trimmed by TD Cowen from $28.00 to $20.00 in a report published on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages also recently issued reports on SGRY. Benchmark restated a “buy” rating on shares of Surgery Partners in a report on Tuesday. Royal Bank Of Canada dropped their price objective on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of Surgery Partners in a research note on Wednesday. Finally, UBS Group decreased their target price on Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Surgery Partners presently has a consensus rating of “Moderate Buy” and an average target price of $24.45.

Surgery Partners Price Performance

Shares of Surgery Partners stock opened at $13.36 on Thursday. The company’s fifty day simple moving average is $15.20 and its two-hundred day simple moving average is $18.11. Surgery Partners has a 12-month low of $12.25 and a 12-month high of $24.64. The firm has a market cap of $1.73 billion, a PE ratio of -21.55 and a beta of 1.95. The company has a quick ratio of 1.72, a current ratio of 1.87 and a debt-to-equity ratio of 1.15.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). The firm had revenue of $885.00 million for the quarter, compared to the consensus estimate of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company posted $0.44 earnings per share. As a group, equities analysts expect that Surgery Partners will post 0.67 EPS for the current year.

Surgery Partners declared that its board has initiated a share buyback program on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 9.7% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Institutional Trading of Surgery Partners

Several large investors have recently bought and sold shares of SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Surgery Partners by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock worth $1,085,000 after acquiring an additional 2,015 shares in the last quarter. Millennium Management LLC boosted its position in shares of Surgery Partners by 1,253.7% during the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock valued at $4,804,000 after purchasing an additional 219,806 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Surgery Partners by 11.0% during the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock valued at $305,000 after purchasing an additional 1,278 shares in the last quarter. AlphaQuest LLC grew its stake in Surgery Partners by 94.4% in the second quarter. AlphaQuest LLC now owns 2,057 shares of the company’s stock worth $46,000 after purchasing an additional 999 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Surgery Partners by 7.5% in the second quarter. Envestnet Asset Management Inc. now owns 32,763 shares of the company’s stock worth $728,000 after purchasing an additional 2,284 shares during the period.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Several analysts maintained buy/outperform ratings despite lowering targets, signaling continued conviction in recovery potential. Analyst Expectations For Surgery Partners’s Future
• Positive Sentiment: TD Cowen cut its price target to $20 but kept a “buy” rating, implying substantial upside from current levels if company execution improves. TD Cowen lowers PT to $20, keeps Buy
• Positive Sentiment: UBS trimmed its target to $21 while retaining a “buy” stance, another signal that analysts still see medium‑term upside despite near‑term weakness. UBS lowers PT to $21, keeps Buy
• Neutral Sentiment: Some commentary frames the current slump as a potential buying opportunity for long‑term investors, but emphasizes execution and margin recovery are key. Has Surgery Partners Slump Opened A New Opportunity For Investors?
• Negative Sentiment: Barclays cut its price target sharply to $14, signaling more conservative near‑term expectations and adding downward pressure on the stock. Barclays Lowers Surgery Partners Price Target to $14
• Negative Sentiment: Q4 results: revenue modestly beat, but EPS missed expectations and management flagged margin pressure — the core reason for the selloff and heightened execution risk. SGRY Q4 2025 Earnings Call Highlights
• Negative Sentiment: Shares hit a new 52‑week low after the earnings miss and analyst downgrades, reflecting elevated near‑term downside and investor concern about margin recovery. Surgery Partners Sets New 52-Week Low on Disappointing Earnings

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.